Prednisolone encapsulated PLGA nanoparticles: Characterization, cytotoxicity, and anti-inflammatory activity on C6 glial cells
Journal of Applied Pharmaceutical Science
Prednisolone, a popular glucocorticoid (GC) known for its ability to inhibit cytokine release, is also employed extensively in cancer therapy. GCs have been used to treat brain tumors to reduce tumor-associated edema. They are known to exhibit different effects on different cell lines and in some cases are known to be neurotoxic. In this study, we have investigated and compared the cytotoxic and anti-inflammatory effects of prednisolone and prednisolone encapsulated Poly Lactic-co-Glycolic acid (PLGA) nanoparticles (NPs) on C6 cells that are cancerous but are known for their similarity to astrocyte cells. Design expert software was used to analyze the effect of different variables for NP formulation. By varying different parameters, NPs were synthesized and characterized using particle size analyzer and zeta potential. The surface morphology of the NPs was analyzed using scanning electron microscopy. Lipopolysaccharide activated C6 glial cells witnessed significantly lower cell proliferation in the presence of the drug during the 48 hours of incubation and the prednisolone encapsulated NPs were able to attenuate pro-inflammatory cytokines like Tumor necrosis factor alpha (TNF-α) and nitric oxide substantially even after the 72 hours of incubation when compared with the free drug. The results suggested that prednisolone was more effective as an anti-inflammatory drug in the PLGA nanoformulation.
Acharya, Sriprasad and Guru, Bharath Raja, "Prednisolone encapsulated PLGA nanoparticles: Characterization, cytotoxicity, and anti-inflammatory activity on C6 glial cells" (2020). Open Access Archive. 397.